Tissue‐specific glucocorticoid excess in the metabolic syndrome: 11β‐HSD1 as a therapeutic target
Author:
- 1 July 2006
- journal article
- Published by Wiley in Drug Development Research
- Vol. 67 (7) , 567-569
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubesEuropean Journal of Clinical Investigation, 2005
- 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in miceJournal of Experimental Medicine, 2005
- Novel Adipose Tissue–Mediated Resistance to Diet-Induced Visceral Obesity in 11β-Hydroxysteroid Dehydrogenase Type 1–Deficient MiceDiabetes, 2004
- Definition of Metabolic SyndromeCirculation, 2004
- A Transgenic Model of Visceral Obesity and the Metabolic SyndromeScience, 2001
- Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11β-Hydroxysteroid Dehydrogenase Type 1 Null MiceJournal of Biological Chemistry, 2001
- Localization of 2 11β-OH Steroid Dehydrogenase Isoforms in Aortic Endothelial CellsHypertension, 1998
- 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stressProceedings of the National Academy of Sciences, 1997
- 1lβ-Hydroxysteroid Dehydrogenase Bioactivity and Messenger RNA Expression in Rat Forebrain: Localization in Hypothalamus, Hippocampus, and Cortex*Endocrinology, 1990
- Prednisolone as an appetite stimulant in patients with cancer.BMJ, 1984